- Home
- ERAS vs ASST Comparison
ERAS vs ASST Comparison
Compare ERAS & ASST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | ASST |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 998.7M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ERAS | ASST |
|---|---|---|
| Price | $12.18 | $9.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $5.78 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 7.1M | 6.2M |
| Earning Date | 03-19-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,512,106.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 125.01 |
| 52 Week Low | $1.01 | $8.81 |
| 52 Week High | $12.48 | $157.80 |
Technical Indicators
Market Signals| Indicator | ERAS | ASST |
|---|---|---|
| Relative Strength Index (RSI) | 81.12 | 77.20 |
| Support Level | $9.05 | $0.49 |
| Resistance Level | $12.48 | $12.25 |
| Average True Range (ATR) | 0.71 | 0.41 |
| MACD | 0.00 | 1.08 |
| Stochastic Oscillator | 87.76 | 74.66 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About ASST Asset Entities Inc. Class B
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.